Latest On Sino Biopharmaceutical Limited (SBHMY):
About Sino Biopharmaceutical Limited (SBHMY):
Sino Biopharmaceutical Limited, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. The company operates in three segments: Chinese Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; oncology medicines comprising Saiweijian injections, Yinishu tablets, Shoufu tablets, Anxian capsules, and Qianping injections; cardio-cerebral medicines, including Yilunping tablets, Tuotuo tablets, and Kaina tablets; and orthopedic medicines, such as Gaisanchun capsules and Yigu injections. The company's principal products also comprise digestive system medicines that consist of Aisuping injections, Getai tablets, and Deyou granules; anti-infectious medicines that include Tiance injections, Tianjie injections, and Tianli injections; respiratory system medicines, such as Tianqingsule inhalation powder; and others comprising Debaian cataplasms. In addition, it engages in property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management consultancy services; and outpatient and surgical procedure. Further, the company manufactures, sells, and distributes health food; and develops medical technology. Sino Biopharmaceutical Limited was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
General
- Name Sino Biopharmaceutical Limited
- Symbol SBHMY
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 24,328
- Last Split Factor1:1
- Last Split Date2020-08-14
- Fiscal Year EndDecember
- Web URLhttp://www.sinobiopharm.com
Valuation
- Trailing PE 35.23
- Forward PE 46.51
- Price/Sales (Trailing 12 Mt.) 5.35
- Price/Book (Most Recent Quarter) 4.15
- Enterprise Value Revenue 0.81
- Enterprise Value EBITDA 3.38
Financials
- Most Recent Quarter 2020-09-30
- Profit Margin 10%
- Return on Assets 4%
- Return on Equity 10%
- Earnings Per Share $0.66
- Revenue Per Share $0
- Gross Profit 19.31 billion
- Quarterly Earnings Growth -19.4%
Highlights
- Market Capitalization 21.76 billion
- PEG Ratio 11.91
- Book Value Per Share $5.00
Share Statistics
- Shares Outstanding 943.08 million
- Shares Float 444.76 million
- % Held by Insiders <1%
Technicals
- Beta 0.56
- 52 Week High $39.55
- 52 Week Low $17.09
- 50 Day Moving Average 20.7
- 200 Day Moving Average 20.01
Dividends
- Forward Annual Dividend Rate $0.21
- Forward Annual Dividend Yield 0.89%
- Payout Ratio 163%
- Dividend Date 2021-01-15
- ExDividend Date 2020-12-11
- Dividend Per Share $0.01
- Dividend Yield 0%
Sino Biopharmaceutical Limited (SBHMY) Dividend Calendar:
SBHMY's last dividend payment was made to shareholders on January 15, 2021.
Sino Biopharmaceutical Limited pays out 163% of its earnings out as a dividend.
Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
---|
Sino Biopharmaceutical Limited (SBHMY) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
---|---|---|---|---|---|
2020-09-30 | 2020-09-30 | $N/A | $0.10 | ||
2020-06-30 | 2020-09-30 | $N/A | $0.01 | ||
2020-03-31 | 2020-06-30 | $N/A | $0.00 | ||
2019-12-31 | 2020-03-31 | $N/A | $0.01 | ||
2019-09-30 | 2019-12-31 | $6.79 billion | $0.00 | ||
2019-06-30 | 2019-09-30 | $6.32 billion | $0.01 | ||
2019-03-31 | 2019-06-30 | $6.21 billion | $0.00 | ||
2018-12-31 | 2019-03-31 | $5.16 billion | $0.01 | ||
2018-09-30 | 2018-12-31 | $6 billion | $0.05 | ||
2018-06-30 | 2018-09-30 | $5.07 billion | $0.01 | ||
2018-03-31 | 2018-06-30 | $4.65 billion | $0.00 | ||
2017-12-31 | 2018-03-31 | $3.37 billion | $0.01 | ||
2017-09-30 | 2017-12-31 | $3.96 billion | $0.00 | ||
2017-06-30 | 2017-09-30 | $277.26 million | $0.01 | $0.00 | |
2017-03-31 | 2017-06-30 | $3.86 billion | $0.00 | $0.00 | |
2016-12-31 | 2017-03-31 | $3.5 billion | $0.01 | $0.00 | |
2016-09-30 | 2016-12-31 | $0.00 | $0.00 | ||
2016-06-30 | 2016-09-30 | $0.00 | $0.00 | ||
2016-03-31 | 2016-06-30 | $0.00 | $0.00 | ||
2015-12-31 | 2016-03-31 | $0.00 | $0.00 | ||
2015-09-30 | 2015-12-31 | $0.00 | $0.00 | ||
2015-06-30 | 2015-09-30 | $0.00 | $0.00 | ||
2015-03-31 | 2015-06-30 | $0.00 | $0.00 | ||
2014-12-31 | 2015-03-31 | $0.00 | $0.00 | ||
2014-09-30 | 2014-12-31 | $0.00 | $0.00 | ||
2014-06-30 | 2014-09-30 | $0.00 | $0.00 | ||
2014-03-31 | 2014-06-30 | $0.00 | $0.00 | ||
2013-12-31 | 2014-03-31 | $0.00 | $0.00 | ||
2013-09-30 | 2013-12-31 | $0.00 | $0.00 | ||
2013-06-30 | 2013-09-30 | $0.00 | $0.00 | ||
2013-03-31 | 2013-06-30 | $0.00 | $0.00 | ||
2012-12-31 | 2013-03-31 | $0.00 | $0.00 | ||
2012-09-30 | 2012-12-31 | $0.00 | $0.00 | ||
2012-06-30 | 2012-09-30 | $0.00 | $0.00 | ||
2012-03-31 | 2012-06-30 | $0.00 | $0.00 | ||
2011-12-31 | 2012-03-31 | $0.00 | $0.00 | ||
2011-09-30 | 2011-12-31 | $0.00 | $0.00 | ||
2011-06-30 | 2011-09-30 | $0.00 | $0.00 | ||
2011-03-31 | 2011-06-30 | $0.00 | $0.00 | ||
2010-12-31 | 2011-03-31 | $0.00 | $0.00 | ||
2010-09-30 | 2010-12-31 | $0.00 | $0.00 |
Sino Biopharmaceutical Limited (SBHMY) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
Date |
---|
Research Development |
Income Before Tax |
Selling General Administrative |
Gross Profit |
Ebit |
Operating Income |
Income Tax Expense |
Total Revenue |
Cost of Revenue |
Total Other Income Expense Net |
Net Income From Continuing Operations |
Net Income Applicable to Common Shares |
Cash Flow:
Date |
---|
Investments |
Change to Liabilities |
Total Cash Flow from Investing Activities |
Net Borrowings |
Total Cash Flow from Financial Activities |
Change to Operating Activities |
Change in Cash |
Total Cash from Operating Activities |
Depreciation |
Other Cash Flow from Investing Activities |
Change to Inventory |
Change to Account Receivables |
Other Cash Flow from Financing Activities |
Change to Net Income |
Capital Expenditures |
Balance Sheet:
Date |
---|
Total Liabailities |
Total Stockholder Equity |
Other Current Liabilities |
Total Assets |
Common Stock |
Other Current Assets |
Retained Earnings |
Other Liabilities |
Other Assets |
Cash |
Total Current Liabilities |
Other Stockholder Equity |
Property, Plant & Equipment |
Total Current Assets |
Long Term Investments |
Net Tangible Assets |
Short Term Investments |
Long Term Debt |
Inventory |
Accounts Payable |
Sino Biopharmaceutical Limited (SBHMY) Chart:
Sino Biopharmaceutical Limited (SBHMY) News:
Below you will find a list of latest news for Sino Biopharmaceutical Limited (SBHMY) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Sino Biopharmaceutical Limited (SBHMY) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
---|
Sino Biopharmaceutical Limited (SBHMY) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
Date | Form Type | Form Name | Link |
---|---|---|---|
2020-01-24 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1604982/000101915520000020/0001019155-20-000020-index.htm |
2014-04-08 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1604982/000119380514000751/0001193805-14-000751-index.htm |
2016-05-25 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1604982/000119380516003321/0001193805-16-003321-index.htm |
2016-09-13 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1604982/000119380516003943/0001193805-16-003943-index.htm |
2017-09-29 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1604982/000119380517002605/0001193805-17-002605-index.htm |
2019-11-22 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1604982/000119380519001656/0001193805-19-001656-index.htm |